Virtu Financial LLC Buys Shares of 138,236 Vaxart, Inc. $VXRT

Virtu Financial LLC acquired a new position in Vaxart, Inc. (NASDAQ:VXRT) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 138,236 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned 0.06% of Vaxart as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Bank of America Corp DE raised its stake in shares of Vaxart by 10.8% in the fourth quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company’s stock worth $122,000 after buying an additional 17,942 shares during the period. Invesco Ltd. raised its stake in shares of Vaxart by 48.6% in the fourth quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company’s stock worth $50,000 after buying an additional 24,803 shares during the period. Graham Capital Management L.P. raised its stake in shares of Vaxart by 155.8% in the fourth quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company’s stock worth $35,000 after buying an additional 32,482 shares during the period. Geode Capital Management LLC raised its stake in shares of Vaxart by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 2,601,139 shares of the biotechnology company’s stock worth $1,723,000 after buying an additional 57,911 shares during the period. Finally, Silverarc Capital Management LLC raised its stake in shares of Vaxart by 7.8% in the fourth quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company’s stock worth $714,000 after buying an additional 77,782 shares during the period. Institutional investors own 18.05% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Vaxart to a “hold” rating in a research note on Thursday, May 22nd.

Vaxart Trading Down 0.4%

Shares of VXRT opened at $0.36 on Tuesday. The business’s 50 day moving average is $0.44 and its 200 day moving average is $0.46. The company has a market capitalization of $83.46 million, a PE ratio of -1.35 and a beta of 1.12. Vaxart, Inc. has a 12-month low of $0.26 and a 12-month high of $1.07.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.